Literature DB >> 11466608

Transcriptional downregulation of ATM by EGF is defective in ataxia-telangiectasia cells expressing mutant protein.

K E Keating1, N Gueven, D Watters, H P Rodemann, M F Lavin.   

Abstract

There is evidence that ATM plays a wider role in intracellular signalling in addition to DNA damage recognition and cell cycle control. In this report we show that activation of the EGF receptor is defective in ataxia-telangiectasia (A-T) cells and that sustained stimulation of cells with EGF downregulates ATM protein in control cells but not in A-T cells expressing mutant protein. Concomitant with the downregulation of ATM, DNA-binding activity of the transcription factor Sp1 decreased in controls after EGF treatment but increased from a lower basal level in A-T cells to that in untreated control cells. Mutation in two Sp1 consensus sequences in the ATM promoter reduced markedly the capacity of the promoter to support luciferase activity in a reporter assay. Overexpression of anti-sense ATM cDNA in control cells decreased the basal level of Sp1, which in turn was increased by subsequent treatment of cells with EGF, similar to that observed in A-T cells. On the other hand full-length ATM cDNA increased the basal level of Sp1 binding in A-T cells, and in response to EGF Sp1 binding decreased, confirming that this is an ATM-dependent process. Contrary to that observed in control cells there was no radiation-induced change in ATM protein in EGF-treated A-T cells and likewise no alteration in Sp1 binding activity. The results demonstrate that EGF-induced downregulation of ATM (mutant) protein in A-T cells is defective and this appears to be due to less efficient EGFR activation and abnormal Sp1 regulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11466608     DOI: 10.1038/sj.onc.1204527

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

1.  Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Authors:  E I Andersson; S Pützer; B Yadav; O Dufva; S Khan; L He; L Sellner; A Schrader; G Crispatzu; M Oleś; H Zhang; S Adnan-Awad; S Lagström; D Bellanger; J P Mpindi; S Eldfors; T Pemovska; P Pietarinen; A Lauhio; K Tomska; C Cuesta-Mateos; E Faber; S Koschmieder; T H Brümmendorf; S Kytölä; E-R Savolainen; T Siitonen; P Ellonen; O Kallioniemi; K Wennerberg; W Ding; M-H Stern; W Huber; S Anders; J Tang; T Aittokallio; T Zenz; M Herling; S Mustjoki
Journal:  Leukemia       Date:  2017-08-14       Impact factor: 11.528

2.  Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis.

Authors:  Jean-Philip Truman; Nuri Gueven; Martin Lavin; Steven Leibel; Richard Kolesnick; Zvi Fuks; Adriana Haimovitz-Friedman
Journal:  J Biol Chem       Date:  2005-04-18       Impact factor: 5.157

3.  Dynamic coregulatory complex containing BRCA1, E2F1 and CtIP controls ATM transcription.

Authors:  Cristian Moiola; Paola De Luca; Javier Cotignola; Kevin Gardner; Elba Vazquez; Adriana De Siervi
Journal:  Cell Physiol Biochem       Date:  2012-07-27

4.  PKCalpha activation downregulates ATM and radio-sensitizes androgen-sensitive human prostate cancer cells in vitro and in vivo.

Authors:  Jean-Philip Truman; Susan A Rotenberg; Ji-Hye Kang; Gabriel Lerman; Zvi Fuks; Richard Kolesnick; Victor E Marquez; Adriana Haimovitz-Friedman
Journal:  Cancer Biol Ther       Date:  2009-01-04       Impact factor: 4.742

5.  Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells.

Authors:  Sarah E Golding; Rhiannon N Morgan; Bret R Adams; Amy J Hawkins; Lawrence F Povirk; Kristoffer Valerie
Journal:  Cancer Biol Ther       Date:  2009-04-22       Impact factor: 4.742

6.  DNA damage alters EGFR signaling and reprograms cellular response via Mre-11.

Authors:  Yael Volman; Ruth Hefetz; Eithan Galun; Jacob Rachmilewitz
Journal:  Sci Rep       Date:  2022-04-06       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.